Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dartmouth-Hitchcock Medical Center
With
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Harvard Medical School (HMS and HSDM)
Commonwealth Research Center, Massachusetts
Novartis
Age
19–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of schizophrenia or schizoaffective disorder
Current diagnosis of an alcohol use disorder with active use in the last 30 days.
The participant (or the participant's authorized legal representative) understands the nature of the study and has he/she signed an informed consent.
Ages 19-65.
Taking olanzapine, risperidone, quetiapine or a typical antipsychotic agent for at least 8 weeks prior to study randomization
If taking depot medication, at least 3 injection cycles since the last injection prior to study randomization.
You may not be if
Contraindication to clozapine
Women who are currently pregnant or who desire to become pregnant during the course of the study.
Current and past treatment with clozapine
Current treatment with agents proposed to curtail substance use (e.g., disulfiram, naltrexone, acamprosate, buspirone) and agents contraindicated for use with clozapine (e.g., inderal, tegretol, lithium).
Meets DSM-IV criteria for current dependence of substances other than alcohol.
Clareo Health | Alcoholism and Schizophrenia: Effects of Clozapine
